from Arimidex)Jump to: navigation, searchAnastrozoleSystematic (IUPAC) name2-[3-(1-cyano-1-methyl-ethyl)- 5-(1H-1,2,4-triazol-1-ylmethyl)phenyl]- 2-methyl- propanenitrileIdentifiersCAS number 120511-73-1ATC code when did arimidex go on the market 2187DrugBank APRD00016Chemical dataFormula C17H19N5Mol. mass 293.366 g/molSMILES eMolecules 293.366.

Norelgestromin, Norethisterone, Norethynodrel, Norgestimate, Norgestrel, Norgestrienone, TiboloneSelective when did arimidex go on the market receptor modulator: Afimoxifene, Bazedoxifene, Clomifene, Fulvestrant, Lasofoxifene, Raloxifene, Tamoxifen, ToremifeneAromatase inhibitor: Aminogluthetimide, Anastrozole, Exemestane, Formestane, Letrozole, VorozoleGonadotropins:(FSHR/LHCGR) ovulation stim.: Clomifene, UrofollitropinAntigonadotropins: Danazol, GestrinoneGnRH:(receptor) agonist: Buserelin, Goserelin, Histrelin, Leuprorelin, Nafarelin, Triptorelinantagonist: Abarelix, when did arimidex go on the market Ganirelix AnastrozoleFrom Wikipedia, the when did arimidex go on the market encyclopedia(Redirected from Arimidex)Jump to: when did arimidex go on the market searchAnastrozoleSystematic (IUPAC) name2-[3-(1-cyano-1-methyl-ethyl)- 5-(1H-1,2,4-triazol-1-ylmethyl)phenyl]- 2-methyl- propanenitrileIdentifiersCAS number 120511-73-1ATC code L02BG03PubChem 2187DrugBank APRD00016Chemical dataFormula C17H19N5Mol. mass 293.366 g/molSMILES eMolecules & PubChemPharmacokinetic dataBioavailability 83-85%Protein.

Excess estradiol in men can cause benign prostatic hyperplasia, gynecomastia, and symptoms of hypogonadism. Some athletes.